News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Subscribe To Our Newsletter & Stay Updated